AI주식인사이트AI Stock Insight
C

펩트론

087010KOSDAQ기초 의약물질 제조업

45.3 / 100

Reference Date: 2026-04-13

Financial Score14.0 / 40
News Sentiment14.3 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, Operating Profit is on a declining trend. Declined 10.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Peptron develops smart pharmaceuticals using peptide engineering and sustained-release technology, operating a GMP large-scale production facility for clinical trials and commercial products. The pharmaceutical industry is characterized by high R&D costs and long-term profitability, with the sustained-release drug sector maintaining an oligopolistic structure due to high manufacturing barriers even after patent expirations.

Number of Employees

160people

Average Salary

58.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 33.454.0Point
PBR
—Industry Average 2.033.5Point
ROE
-9.41Industry Average -4.293.5Point

2.2x industry avg (excellent)

Debt Ratio
21.10Industry Average 6.610.0Point

3.2x industry avg (risky)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲36.5% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼16.3% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -22.9% (improving, 3yr)

Detailed News Sentiment

11 totalPositive 4Neutral 2Negative 0Average Sentiment Score 63.3

Detailed Momentum

52-week position5.0Point

52w mid range (49%)

Current 267,500Won52-week high 386,00052-week low 153,200
1-month return1.0Point

1m -10.23% (falling)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-03-31
  • Neutral주식매수선택권부여에관한신고2026-03-26
  • Neutral정기주주총회결과2026-03-26
  • Neutral기업설명회(IR)개최2026-03-20
  • Neutral감사보고서제출2026-03-18